Tepotinib
Tepotinib, sold under the brand name Tepmetko, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. It is a c-Met inhibitor, a type of tyrosine kinase inhibitor.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Tepotinib
Tepotinib, sold under the brand name Tepmetko, is a medication for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. It is a c-Met inhibitor, a type of tyrosine kinase inhibitor.
has abstract
Tepotinib, sold under the bran ...... r mutations, after capmatinib.
@en
alternative name
Tepmetko
@en
CAS number
1100598-32-0
ChEMBL
DrugBank
FDA UNII code
1IJV77EI07
PubChem
Link from a Wikipage to an external page
Wikipage page ID
57,625,130
page length (characters) of wiki page
Wikipage revision ID
1,006,695,343
Link from a Wikipage to another Wikipage
ATC prefix
L01
@en
ATC suffix
EX21
@en
CAS number
ChEMBL
ChemSpiderID
25,069,712
DailyMedID
Tepotinib
@en
DrugBank
DB11791
@en
image
@en
index2 label
as HCl
@en
IUPAC name
KEGG
D11073
@en
D11717
@en
legal status
Rx-only
@en
legal US
Rx-only
@en
pregnancy category
Not recommended
@en
PubChem
25,171,648
routes of administration
SMILES
CN1CCCCOC2=CN=CC3=CC=CCCN4CC=CCC5=CC=CCC#N
@en
StdInChIKey
AHYMHWXQRWRBKT-UHFFFAOYSA-N
@en
synonyms
EMD-1214063
@en
tradename
Tepmetko
@en
wikiPageUsesTemplate
comment
Tepotinib, sold under the bran ...... of tyrosine kinase inhibitor.
@en
label
Tepotinib
@en